{{ subpage.title }}

Grading President Biden's first 100 days; 2020 US Census helps Sun Belt states

Get insights on the latest news in US politics from Jon Lieber, head of Eurasia Group's coverage of political and policy developments in Washington:

How would you grade President Biden's performance in his first 100 days?

Well, Biden's done pretty well in this first 100 days. He's done a good job on what's the number one most important issue facing his administration and that's the coronavirus response. He hit his goal of 100 million vaccinations within the first month or so of his administration. And they increased that to 200 million vaccinations, which they hit on day 92. So that's a pretty successful start. They inherited a lot of that from President Trump to be fair. Operation Warp Speed set the US up for success and Biden delivered after he came into office. And of course, the second thing is his COVID relief package, which the US has taken advantage of a favorable funding environment to borrow trillions of dollars and get them into the hands of American small businesses and families and has really helped the economy through what has been a very bad year but could have been a lot worse if the government hadn't intervened. The bill has been very popular, and it set the stage for a follow on bill that Biden wants to deliver for big priorities for democrats later this year, potentially as much as $4 trillion in spending.

Read Now Show less

Operation Warp Speed: Does credit for Moderna’s COVID vaccine go to the US taxpayer?

Without the help of the US government initiative "Operation Warp Speed," Moderna co-founder Noubar Afeyan says that it would have been impossible for the company to develop and deliver its vaccine so quickly. The fact, he says, that the American people may be days away from receiving its first doses is, in large part, thanks to their taxpayer dollars. Does President Trump, himself, deserve credit? "Without caveat," Afeyan says. He spoke with Ian Bremmer on GZERO World.

Watch the GZERO World episode: A Shot in the Arm: Moderna's Co-Founder on the COVID-19 Vaccine

How development of the COVID-19 vaccine shattered records

They said it couldn't be done: a vaccine developed in record time. In 1967, Merck had a license for a mumps vaccine, less than five years for work that normally takes decades. But that record is now being shattered as the COVID-19 vaccine reaches the market in less than a year. It's an unprecedented scientific development in a whirlwind year of crisis.

Watch the GZERO World episode: A Shot in the Arm: Moderna's Co-Founder on the COVID-19 Vaccine

Quick Take: Latest vaccine news may be a light at the end of the tunnel

Ian Bremmer's Quick Take:

Hey, everybody. Ian Bremmer here, happy Monday, Thanksgiving week. Things starting to look increasingly normal in terms of outlook, in terms of having all of these vaccines. I understand that the next few months in the United States are going to be incredibly challenging, but so much easier when you see that there's light at the end of the tunnel and you know where that's coming. Most recently, the AstraZeneca announcement, which for me, in some ways is a bigger deal globally, even than what we've seen from Moderna and Pfizer, because it doesn't require freezing, it's just refrigeration, which means that countries around the world that don't have the infrastructure to deal with this cold chain requirements of these vaccines will be able to use another set of vaccines with different technology. That's not just AstraZeneca, it will be Johnson and Johnson. It's the Russians. It's the Chinese.

Read Now Show less

Subscribe to GZERO Media's newsletter, Signal

Latest